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I INTRODUCTION
We are creatures of habit. This is evident in our molec-
ularly derived need for sleep. Beneath those molecules
are a highly conserved set of genes that encode for the
adaptation to our planet’s 24 h solar cycle. Environmental
signals like light, social interactions, and food provide
the cues necessary for the regular organization of cellu-
lar function, culminating in efficient organismal behav-
ior. Sleep is a required behavior for most organisms
(Chong, Xin, Ptacek, & Fu, 2015). The conceptual frame-
work for sleep proposes that sleep need and the timing
of sleep are integrated processes. Sleep therefore can
be divided into processes controlling the timing of sleep
(Process C) and the drive for sleep (Process S) (Borbely &
Wirz-Justice, 1982; Fisher, Foster, & Peirson, 2013). In
humans, under normal conditions, a circadian rhythm
(which is believed to drive Process C) “primes” the body
to consolidate the timing of sleep to epochs of time when
the functions of sleep are most efficient. The sleep homeo-
stat (believed to drive Process S) regulates the duration of
sleep so that “sleep need” is met and appropriate vigi-
lance, cognition, and motor functions can be restored
for the following wake period. Thus, these two processes
dictate when and how we sleep.
The biological consequences of sleep and circadian dis-
ruption are becomingmore apparent, yet societal demands
on personal schedules and sleep patterns remain high. Epi-
demiological data in Americanworkers point to the steady
reduction in sleep length over the past 50 years (Kraus &
Rabin, 2012), with fluctuations in sleep duration between
the workweek and weekend (Roenneberg, Allebrandt,
Merrow, & Vetter, 2012). Sleep deprivation, social jet lag,
chronic sleep restriction, and circadian desynchrony have
been associated with a variety of medical comorbidities,
including cancer (Haus & Smolensky, 2013), metabolic
and immune dysfunction (Eckel-Mahan & Sassone-Corsi,
2013; Prather, Janicki-Deverts, Hall, & Cohen, 2015;
Roenneberg et al., 2012), and cognitive and psychiatric
alterations ( Jagannath, Peirson, & Foster, 2013; Leung
et al., 2015). Clearly, the incidence of sleep disruption is
significant and likely will continue to increase. Thus, the
comorbid consequences on human health could be enor-
mous on a population scale. It is estimated that 50–70
million individuals suffer from chronic sleep disorders in
the United States alone (Colten & Altevogt, 2006). A call
for further investigations of sleep and circadian rhythm reg-
ulation has implications for not only novel treatment of
sleep disorders but also the improvement of the efficacy
and safety of existing therapies if they can be administered
in the context of an appropriate, individualized biological
phase (chronotherapy) (Hermida et al., 2013).
A better understanding of the molecular pathways
governing the timing and duration of sleep leads to
increased clarity of the roles of sleep and circadian dis-
ruption on these processes. The fundamental machinery
underlying circadian rhythms has largely been eluci-
dated in model systems such as Drosophila and mouse
(Mohawk, Green, & Takahashi, 2012; Rosbash, Allada,
Dembinska, Guo, & Marrus, 1996). Each cell in the body
has a molecular clock that governs the expression of
clock-controlled genes (a percentage of the genome),
which varies depending on the cellular subtype (Bozek
et al., 2009; Keller et al., 2009), to provide a periodicity
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(the time required for one complete oscillation to occur)
or phase (e.g., time of awakening relative to start of the
solar day).
The clock itself can be described as a series of highly
coordinated, autoregulatory feedback loops. The core
heterodimer of the clock is made up of the proteins
CLOCK and BMAL1, which activate transcription of
genes that have clock gene promoters (E-box elements).
CLOCK/BMAL1 drives the transcription of negative
and stabilizing regulatory loops of the clock itself, includ-
ing three period genes (PER1, PER2, and PER3) and two
cryptochrome genes (CRY1 and CRY2) that represent a
cohort of negative regulatory proteins. PER and CRY
are posttranslationally modified and heterodimerize
and enter the nucleus where they inhibit CLOCK-/
BMAL1-mediated transcriptional activity. This process
occurs reliably in a roughly 24 h period that can be reset
by external cues (i.e., peripheral mediators from the SCN
or, in the case of the SCN itself, light) and provides a cell-
autonomous timekeeping process. Many other proteins
are under clock control that affect clock stability and
function. TIMELESS functions in the mammalian clock
by binding PER and CRY and has independent transcrip-
tional repressor activity of core clock machinery (Gotter,
2006). CLOCK/BMAL1 also mediates transcription of
Rev-ERBa and RORa that inhibit and activate the tran-
scription of BMAL1, respectively. Similarly, E4BP4 nega-
tively regulates and DBP positively regulates D-box
elements in clock genes, which contributes to rhythmic
transcription of RORa among other components of the
clock. Other components of the circadian clock regulatory
machinery have been identified, such asDEC1 andDEC2,
which repress the transcriptional activity of CLOCK/
BMAL1 at promoter sites.
Adding another layer of regulation, many of these pro-
teins are posttranslationally modified to affect stability
and speed of the clock. Casein kinase 1 epsilon and delta
(CK1ε and CK1δ) regulate the negative feedback loop of
the clock by phosphorylating specific residues on PER
proteins. Depending on the site of phosphorylation, pro-
tein translocation to the nucleus can be promoted, or
other sites can prioritize protein turnover. Additionally,
posttranslational regulation by O-GlcNAcylation (an
event mediated partially by glucose levels) of PER2 com-
petes with phosphorylation to further regulate the circa-
dian clock (Kaasik et al., 2013). In any case, the PER/CRY
heterodimer is the key negative regulator of the canonical
clock, and ultimately, the transcriptional activity of
CLOCK/BMAL1 is altered if PER/CRY is destabilized,
leading to a change in clock speed and/or phase. Because
many of the aforementioned proteins have multiple
binding partners, it is likely that they have secondary
or tertiary effects on other physiological processes out-
side their primary roles in clock regulation (Grimaldi
et al., 2010). The molecular pathways regulating sleep
homeostasis remain less well defined and present an
exciting and challenging frontier of investigation. Indeed,
many of these clock genes have associations with sleep
regulation, providing an initial window into the con-
nectivity between circadian processes and parameters
of sleep, thus reinforcing the idea that sleep is perhaps
gated by the circadian clock (Fisher et al., 2013;
Mang & Franken, 2013).
Some heritable sleep conditions, such as familial
advanced sleep phase (FASP) and familial natural short
sleep (FNSS), were previously termed as disorders but
have since been reclassified as traits because of the per-
ceived advantage (by many) that they confer to carriers.
We consider them “disorders” only in cases where
affected individuals are troubled by the trait. Interest-
ingly, genetic drift selects against populations ofmice car-
rying the tau mutation in casein kinase 1ε (which causes
shortened period and accelerated free-running circadian
cycles), when allowed tomate freely over time (Spoelstra,
Wikelski, Daan, Loudon, & Hau, 2016). Yet, our uniquely
human environment and social demandsmay be a reason
why these traits exist in the larger population. Studies of
twins leads to estimates of genetic contributions to sleep
quality (33%) and to sleep pattern (as defined by bedtime,
sleep time, sleep duration, and daytime napping) (40%)
(Heath, Kendler, Eaves, & Martin, 1990) establishing
precedence for studying the genetics contributing to a
complex behavioral trait. By studying individuals with
heritable sleep traits, we are able to clarify mechanistic
details of sleep or circadian regulation and also to identify
phenotypes that are stable at the human organismal level,
thus providing an unprecedented approach to identify-
ing putative therapies for sleep and circadian disorders
affecting the larger population. The relative conservation
of genes across species underlies the fundamental impor-
tance of these pathways in regulating the critical physio-
logical process of circadian regulation and sleep. Because
these pathways exist in humans, the confirmation, post-
transcriptional regulation, and fine-tuning of these
molecular elements have been significantly impacted
by human genetics and in particular forward genetic
screens using human subjects with heritable sleep traits
(which will be discussed in detail in the following text)
(Hsu, Ptácek, & Fu, 2015).
In this chapter, we will outline an approach to identi-
fying specific causative mutations for circadian traits that
alter the timing of sleep-wake behavior and characteriz-
ing these alleles in the laboratory. We will provide addi-
tional information from selected genetic association
studies for single-nucleotide polymorphisms (SNPs)
linked to circadian conditions. Alleles discovered using
the same approaches that inform the regulation of
homeostatic sleep drive will also be outlined briefly.
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II METHODOLOGY
Themain goal of research into the genetic basis of sleep
and circadian traits is to identify specific variants in the
genome that cause phenotypes and then to study the
mechanisms by which these mutations lead to the sleep
or circadian trait. Studying sleep behavior is complicated.
Because sleep research is a relatively nascent field with its
modern origins in the early 1970s, the classification of
sleep disorders is still developing, both in terms of iden-
tified diseases/traits and refinement of phenotyping
of such diseases/traits. Sleep and circadian traits are
complex behaviors, and they are genetically andmechanis-
tically diverse. Inherent genetic and biological tendencies
are subject to external factors, which can be confounding.
Some of these confounds include considerable variability
in assessed phenotypes, overlapping psychological pathol-
ogy, environmental factors like medication or other
drugs, social and cultural influences, and school/work
pressures, all of which make objective assessments of sleep
in large populations difficult to obtain (Chong et al., 2015;
Hsu et al., 2015; Veatch, Keenan, Gehrman, Malow, &
Pack, 2017).
To achieve this goal, there are generally two genetic
approaches that have been applied to study sleep behav-
ior, and they differ largely in the subjects that are used as
inputs for study. One approach, known as genome-wide
association studies (GWAS), centers on an unbiased
assessment of associations between specific phenotypes
and gene variants across many thousands of genomes.
The other, known as a forward genetic approach, focuses
on very careful phenotyping of affected individuals
within families to identify genetic variants by candidate
gene sequencing and whole-exome or whole-genome
sequencing that segregates with the affected familymem-
bers. Once a putative allele is identified, modeling of this
mutation is done in vitro and in vivo in animal models to
determine whether the allele is sufficient to reproduce the
phenotype, with the given caveats and limitations of
behavioral or molecular differences in various model
systems.
Genome-wide association studies: With access to the
genomic data from thousands of individuals from accu-
mulated sequencing projects, there is an increasing ability
to correlate genetic variants to specific traits, in addition
to providing a greater understanding of the genetic var-
iations that exist in the human population. Genome-wide
association studies (GWAS) are observational studies
that seek associations between traits or diseases in a pop-
ulation of participants with specific genetic variants
across their sequenced genomes. This approach is gener-
ally considered to be hypothesis-free (Gehrman, Keenan,
Byrne, & Pack, 2015). If a variant segregates with a dis-
ease, then that region of the genome, allele, or even a
specific SNP may contain information that contributes
to the development of that disease. GWAS studies focus
on common genetic variants that reach statistical signifi-
cance but typically have very small effect sizes on com-
plex phenotypes, which certainly is applicable to the
complex behaviors related to sleep regulation. Because
of the stringent statistical thresholds required for GWAS
and the expected small effect size, these studies require
sequencing data from many thousands of individuals
(Gehrman et al., 2015). While these studies have yielded
some interesting findings, many associations have not
been replicated, thus calling into question whether the
association is real. Also, for every association reported,
very few have been followed up to determine the genetic
and molecular basis of the genetic variant causing
increased risk for that phenotype. Another problem with
GWAS is that such associations do not necessarily repre-
sent the causative variant, which may be in linkage
disequilibrium with the phenotype in question. Further,
even if a variant that contributes to increased risk of a
disease is identified and resides in noncoding sequences,
it is not necessarily given that it acts via the nearest gene.
Some intronic and intragenic variants can act on gene
regulation more remotely. Thus, without detailed func-
tional work to define the relevant gene/pathway in
which a risk allele may act, determining its precise con-
tributions to pathophysiology remains largely specula-
tive. In contrast, a forward genetic approach in families
with Mendelian inheritance of a trait incorporates molec-
ular and biochemical experimentation to demonstrate
causality.
Forward genetic approaches: Because complex behavior
has many potential confounding factors that make an
analysis of causative alleles difficult, the second approach
focuses on clinical diagnosis where these sleep and circa-
dian behavioral variables are meticulously accounted for
before elucidating a genetic cause. So far, this approach
has been used successfully in characterizing familial
advanced phase (FASP) and familial natural short sleep
(FNSS) phenotypes.
FASP is a trait where affected individuals in a family
wake up and sleep at much earlier times than unaffected
members, while sleep quality and quantity are normal
( Jones et al., 1999). FNSS is a trait where affected family
members sleep significantly less than unaffected mem-
bers but with normal circadian timing. The first step in
studying the genetics of these traits is to identify affected
and unaffected individuals in families through rigorous
phenotyping. Careful attention must be paid to extreme,
yet normal (nongenetic), variation in sleep onset and
duration, adherence to established thresholds (defined
to select for extreme phenotypes), and environmental
or psychological influences that interfere with the pheno-
type of interest (Hsu et al., 2015). Subjects are recruited
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either by referral from clinicians or by self-referral. Once
identified, previous successful studies have demon-
strated that selecting probands with relatively large devi-
ations from the population mean can improve the effect
size. The appropriate selection parameters for FASP are
a sleep onset prior to 8:30 p.m. and spontaneous awaken-
ing before 5:30 a.m. and a sleep duration of 6.5 h or less
for FNSS (Hsu et al., 2015; Jones, Huang, Ptácek, & Fu,
2012). Clinical evaluation of other health conditions
and medications is imperative to determine their con-
tributions to the phenotypes of interest. Also, special
attention must be paid to environmental influences,
such as exposure to light in the sleeping period, which
is integrated into the patient evaluation. The use of
established questionnaires and structured interviews is
designed to distinguish innate sleep preferences from
social and environmental obligations confounding sleep
behavior. The Horne-Ostberg morning-eveningness
(Horne & €Ostberg, 1976) and Munich Chronotype ques-
tionnaires (Roenneberg, Wirz-Justice, & Merrow, 2003)
differentiate between the preference for a sleep pattern,
as compared with the actual sleep patterns. Further, the
Epworth and Karolinska sleepiness scales are valuable
in assessing the sufficiency of sleep in a given individual
(Åkerstedt & Gillberg, 1990; Hsu et al., 2015; Johns, 2002).
Following up on self-reported data first involves a
structured interview that focuses on identifying environ-
mental (psychosocial and familial-cultural) influences
that might alter the biological (genetic) timing of sleep.
Whenever possible, it is worthwhile to gather objective
data to help characterize either advanced sleep phase
(ASP) or natural short sleep (NSS) behaviors, including
sleep logs, actigraphy, and measurement of melatonin
profiles. Further, there are a variety of more labor-
intensive approaches to analyze circadian cycles and
sleep patterns in humans, including polysomnography
in a sleep lab or (via telemetry) in the home environment.
The objective assessment of ASP usually involves an
extended period in a constant environment with mini-
mized exposure to environmental time cues (free run-
ning) (Kleitman & Kleitman, 1953) or by imposing the
subject to 20–28 h of rest-activity periods (forced desyn-
chrony) (Dijk, Duffy, Kiel, Shanahan, & Czeisler, 1999).
These manipulations allow the assessment of endoge-
nous circadian period, which, if shortened, has been
shown to cause FASP (Hsu et al., 2015). Obviously, there
are challenges with subjecting research subjects to these
intensive and costly assays. Other analyses that focus
on phase can follow surrogates of circadian rhythmicity
to assess for physiological circadian peaks and nadirs rel-
ative to time cues in a noninvasive manner. The best
example of this is the use of salivary melatonin levels
to assess dim light melatonin onset (DLMO), since the
circadian-derived peak of melatonin correlates with the
onset of sleep timing (Lewy, 2007), which is expected to
shift forward in FASP subjects relative to unaffected con-
trols ( Jones et al., 1999). The use of actigraphic measures
can also provide further insight into rest-activity patterns
in the real world, especially when used in the general
population, and may be a useful tool for future investiga-
tions of phase and short sleep phenotypes.
Objective assessment of NSS is centered on quantify-
ing not only the duration of sleep but also the parameters
that define the homeostatic sleep pressure (Process S) in
both wake and sleep. To that effect, actigraphy may be
useful to measure inactivity as a surrogate for the dura-
tion of sleep. However, even though actigraphy can be
employed as an initial screening tool, electroencephalog-
raphy (EEG) remains the gold standard for markers of
sleep pressure. In particular, EEG data provide precise
information about the onset and offset of sleep, the timing
of various sleep stages, and the intensity and specific EEG
frequency components of sleep. For example, slow-wave
activity (frequency 0.5–4 Hz) is a marker of sleep depth in
NREM epochs and sleep drive during the course of wak-
ing periods (Dijk, Beersma, & van denHoofdakker, 1989).
Responses to sleep deprivation can also be studied using
the EEG, with NSS individuals presumably exhibiting
reduced NREM and REM duration in normal sleep and
reduced NREM and REM during the recovery period
after sleep deprivation.
Once an individual is classified as a carrier of the trait,
DNA samples are collected from as many informative
individuals in the kindred as possible, including both
affected and unaffected (at-risk) members of the family
and both parents. The primary samplingmethod is to col-
lect blood, where high-quality DNA can be extracted and
analyzed using a variety of genetic sequencingmethodol-
ogies. Using this forward genetic approach, we have
focused on phenotypes that have an autosomal dominant
pattern of inheritance. Because the incidence of FASP and
FNSS are relatively low in the population, the implicated
alleles are likely rare variants with a large effect size for
the phenotype (Hsu et al., 2015). For large families with
multiple affected family members, linkage analysis can
be performed to rule out large parts of the genome. Link-
age analysis takes advantage of the fact that SNPs
(markers) that are in close proximity to causative alleles
on chromosomes are more likely to be passed down to
offspring (after meiosis) than genes that are farther away
(Gehrman et al., 2015; Hsu et al., 2015). Thus, the locus
harboring the disease variant can be identified by track-
ing and comparing the marker and phenotype between
affected and unaffected family members, as was done
in the original characterization of FASP. The maximum
likelihood logarithm of odds (LOD) score is a statistical
measure of the likelihood of linkage for each identified
region. Higher LOD scores indicate a greater significance
of linkage with the phenotype (vs the alternative
hypothesis, i.e., that they are cosegregating based on
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chance). A LOD score of 3 is considered statistically
significant for linkage (Gehrman et al., 2015; Hsu et al.,
2015). Once a statistically significant LOD score impli-
cates a locus as being linked, fine mapping is performed
to define the minimum critical region where a causative
mutation must reside. Sequencing genes in this chromo-
somal region of interest can then identify the specific
causative mutation.
A majority of identified FASP and FNSS kindreds are
characterized based on definitive information from only a
small number of family members (two to three affected
individuals). In this case, it is not possible to definitively
map the genomic locus. However, studies of cosegrega-
tion of candidate mutations with the phenotype are help-
ful in ruling out many variants (Hsu et al., 2015). To
identify associated alleles in these families, a candidate
gene (using a priori information from previous studies)
approach has been very successful for FASP, but is not
possible for FNSS, given the current limited understand-
ing of the molecular regulators and pathways governing
homeostatic sleep. Another powerful approach is whole-
exome/whole-genome sequencing in groups of affected
individuals, which allows the identification of a large
number of variants that can then be sifted and prioritized
to define a list of high-priority putative causative alleles
for further investigation. In such studies, the strongest
genetic data are provided by identifying multiple rare
alleles in the same gene in DNA from unrelated individ-
uals with the same phenotype. To addweight to causality
of a particular allelic variant, consideration of sequence
homology across phylogeny points to functional impor-
tance and, thus, provides strong support for a (causal)
role of a specific variant. This approach has been success-
fully applied to small kindreds in prior studies (Hirano
et al., 2016; Xu et al., 2005; Zhang et al., 2016) but should
nevertheless be employed cautiously, as there is little sta-
tistical support for identified disease alleles (Hsu et al.,
2015). Further characterization of these alleles in model
systems (in vitro and in vivo) becomes essential to substan-
tiate causality.
III HERITABLE SLEEP TRAITS
The most recent International Classification of Sleep
Disorders (ICSD) lists roughly 60 disorders of sleep in
humans (Sateia, 2014). A smaller subset of these condi-
tions has been recognized to have a heritable component.
Similar to the parsing of sleep into Processes C and S,
these heritable conditions largely fall into either those
that broadly affect circadian rhythmicity or sleep homeo-
stasis/duration.While it is plausible that there are pheno-
types that affect both Processes C and S, they have
yet to be linked to novel alleles, or established variants
have been insufficiently studied to identify the overlap.
Among the various classified sleep homeostasis/duration
conditions, narcolepsy, restless leg syndrome, obstructive
sleep apnea, fatal familial insomnia, natural short sleep
(NSS), and REM sleep behavior disorder have varying
levels of defined heritability. There are fewer recognized
circadian traits, comprising six distinct entities: advanced
sleep phase (ASP), delayed sleep phase (DSP), shift work
disorder, jet lag disorder, free-running sleep (or non-24
hour sleep-wake rhythm) disorder, and irregular sleep-
wake disorder, with ASP and DSP having genetic associ-
ations. In the remainder of the text, we will focus on the
traits that are involved with the timing of sleep-wake
behavior, with a specific focus on a detailed discussion
of ASP. Further, wewill outline the genetic variations con-
tributing to the altered sleep homeostasis/duration in
humans with a focus on NSS.
Morning or evening preferences (as assessed by Horne-
Ostberg questionnaires to classify individuals as “typi-
cally” morning or evening types) are linked to SNPs,
many of which are in known circadian clock genes. One
polymorphism is in the CLOCK gene in the 30-
untranslated region of the transcript (Zhang, Ptácek, &
Fu, 2013). Carriers show a delay in preferences for sleep
and activity that ranges from 10 to 44 min compared with
noncarriers (Benedetti et al., 2008; Garaulet et al., 2011;
Mishima, Tozawa, Satoh, Saitoh, &Mishima, 2005). SNPs
in NPAS2 are associated with the self-reported timing of
sleep and adaptability and sleepiness in nurses on shift
work schedules; interestingly, both of these SNPs localize
to intron three of the NPAS2 gene (Gamble et al., 2011).
A locus in exon 18 of the PER1 gene is associated with
extreme morning and evening preferences. The 2434
T/C allele is a silent variation, where the C in this posi-
tion associates with extreme morning preference com-
pared with subjects with extreme evening preferences
(Carpen, Von Schantz, Smits, Skene, & Archer, 2006).
PER2 is linked to diurnal preference, with an SNP in
the 50-UTR-111G upstream of the start codon causing a
predicted alteration of the mRNA secondary structure,
leading to an association with extreme morning prefer-
ences (Carpen, Archer, Skene, Smits, & Von Schantz,
2005). A second missense variant in PER2 (1244 Gly/
Glu) is also associated with morningness in a Korean
population (Lee et al., 2011). The consistent association
of morning or evening preferences with genetic variants
in identified circadian clock genes reinforces the role of
the clock in the timing of sleep-wake behavior.
Delayed sleep phase (DSP) is characterized by sleeping
and waking significantly later than the majority of the
population. Phase advances and delays are considered
“disorders” only when the trait is perceived negatively
by the individual, which is more common with DSP than
with ASP. Such cases lead to the diagnosis of either DSP
disorder (DSPD) or ASP disorder (ASPD). Individuals
with DSPD often have significant conflicts with expected
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social and work requirements that adhere to schedules
based on optimal timing for unaffected individuals. As a
result, DSPD patients are often (incorrectly) diagnosed
with insomnia, because of excessive daytime fatigue
resulting from their attempts to adhere to “normal” sched-
ules (Chong et al., 2015; Jones et al., 2012). Specifically,
these individuals initiate sleep well after midnight and
prefer to wake up in the late morning or afternoon; some
cases of DSPD exhibit a delayed phase of melatonin
rhythms to corroborate a shifted sleep-wake phase
( Jones et al., 2012). This condition has been associatedwith
mutations in aralkylamine N-acetyltransferase (AANAT,
the rate-limiting enzyme functioning in the synthesis of
melatonin) (Hohjoh et al., 2003) and the PER3 variable
number tandem repeat locus (discussed later), but further
genetic evidence or confirmation in model systems is lack-
ing (Archer, Schmidt, Vandewalle, &Dijk, 2018). A variant
in CRY1 (c.1657+3A>C) was recently identified to be a
likely causal mutation for DSP based on a detailed pheno-
typing of a single proband and a control subject and sub-
sequent candidate gene sequencing of the proband’s small
kindred (Patke et al., 2017). This variant is situated at a
position that causes splice site disruption and exon skip-
ping, thereby producing an in-frame deletion of 24 amino
acids in the C-terminal region of the protein. This deletion
causes increased repressor activity of CRY1 for the
BMAL/CLOCK heterodimer in vitro and lengthens circa-
dian period in cell culture systems. Because this allele has a
frequency of up to 0.6% (based on available genomic data-
bases), the authors were able to reverse phenotype 70 sub-
jects (homozygotes, heterozygotes, and noncarriers) in six
unrelated families. Of the 38 carriers of the CRY1 mutant
allele, most reported sleep disturbances inclusive of
delayed sleep times and increased sleep fragmentation
(Patke et al., 2017). Although there is in vitro evidence sup-
porting the possible causal role of the variant, it remains to
be demonstrated that the variant will produce similar phe-
notype in a mammalian model system such as mouse.
Familial advanced sleep phase (FASP): ASP is a condition
where affected individuals have earlier sleep and wake
times than unaffected individuals. The criteria for the
clinical diagnosis of ASPD are based on a patient’s com-
plaint of a sleep time that is earlier than his/her “desired”
sleep schedule ( Jones et al., 2012). We defined FASP in
families segregating ASP as an autosomal dominant trait.
Individuals with FASP experience pronounced difficulty
staying awake in the evening and an obligate need to
wake up significantly earlier than nonaffected individ-
uals. Among affected individuals in a family, some are
troubled by the trait, others are indifferent to it, while
yet, others feel “virtuous” for being the “early bird that
gets the worm.”
When first described, the proband presented to the
clinic with “disabling early evening sleepiness and early
morning awakening” ( Jones et al., 1999) and the
recognition that other family members had similar traits
lead to the classification of heritability ( Jones et al., 1999;
Toh et al., 2001). The phenotype is segregated in a highly
penetrant autosomal dominant manner in this family.
The typical onset of FASP is relatively early in life, with
the youngest affected individual being 8 years old and
most affected family members being aware of their early
morning preferences by the age of 30. The proband had a
dramatic advancement in sleep phase of 4–6 h compared
with controls, subsequently affected familymembers also
showed objective phase advance of nearly 4–6 h in sleep
onset and offset, DLMO and temperature nadir com-
pared with unaffected family members. Overall quality
and quantity of sleep, as measured by polysomnography,
were normal. One affected individual in the kindred was
studied in a time isolation facility, and her endogenous
circadian period, as measured by sleep-wake activity pat-
terns and temperature data, was shortened to 23.3 h com-
pared with 24.2 h in matched controls ( Jones et al., 1999).
Based on these data, FASP was defined as an autosomal
dominant human sleep trait characterized by stable
entrainment of sleep and wakefulness to early solar times
( Jones et al., 2012).
To determine the genetic basis of FASP in this exten-
sively phenotyped large kindred, linkage analysis was
performed, which mapped the location to chromosome
2qter with a LOD score of 5.25. Further investigation into
this region revealed approximately 40 cDNAs, all of
which were sequenced, recognizing PER2 as one of the
candidates (Toh et al., 2001). Sequencing the PER2 gene
in the FASP kindred revealed four changes, three of
which were at wobble positions, but the fourth base
change at position 2106 (A–G) was predicted to cause
an amino acid substitution from serine to glycine at posi-
tion 662 in the PER2 protein (S662G). This mutation seg-
regated with the affected individuals in the family and
was not found in control samples. To test the functional
consequences of this mutation, in vitro experiments were
performed using PER2 truncation mutants and immuno-
precipitation assays to show that the S662G mutation
resides within a CK1-binding domain. Assaying gel-
mobility shifts of wild-type (WT) or mutant PER2
fragments incubated with CK1 revealed that the S662G
mutation abolished phosphorylation in this region.
Consistent with the CK1 recognition motif (S-X-X-S-),
amino acid sequences of the residue downstream to S662
showed serines at positions 665, 668, 671, and 674.Mimick-
ing phosphorylation at 662 by substituting the serine
with phosphomimic aspartate (S662D), CK1-dependent
phosphorylation was restored to the subsequent serines
(665, 668, 671, and 674) suggesting CK1 is responsible
for the phosphorylation of these subsequent serines. Addi-
tional studies confirmed this result by using PER2 peptide
fragments with a covalently linked phosphate at serine
662 (Xu et al., 2007). Separate investigations using cell
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culture demonstrated that the PER2 S662G mutation
results in reduced protein stability (Vanselow et al.,
2006), suggesting alternative sites of phosphorylation that
may target the protein for degradation. Itwas reported that
CK1-mediated phosphorylation of PER at these alternative
sites leads to the recruitment of specific ubiquitin ligases,
causing ubiquitylation and degradation of PER (Eide
et al., 2005; Luo et al., 2009; Reischl et al., 2007; Zhang
et al., 2013). Furthermore, CK1 was recently identified
as the kinase responsible for phosphorylating PER2
S662 (Fustin et al., 2018; Narasimamurthy et al., 2018).
These data demonstrate that the PER2 S662G mutation
causes a deficit in phosphorylation at a key priming site
required for a downstream phosphorylation cascade by
CK1 and alters its stability, possibly by unbalanced
phosphorylation.
These studies unveiled important pathways for the
regulation of PER2 in vitro, but modeling of this mutation
in mouse models provided the necessary step in under-
standing FASP. Transgenic mouse models carrying the
mutant human (h) PER2 S662G, S662D, and wild-type
(WT) sequences with the appropriate regulatory domains
were generated (Xu et al., 2007). Behavioral analysis of
these animals demonstrated a recapitulation of the FASP
phenotype. hPER2-S662G animals had a dramatically
shortened period of 22 h in constant darkness (DD) and
a 4–6 h phase advance of rest/activity rhythms in 12 h
light/12 h dark (LD 12:12). The hPER2-S662D mice had
period lengthening of 0.5 h in DD and did not display
a change of phase in LD 12:12, and hPER2 WT mice
had normal period of 23.7 h and normal phase. Analysis
of PER2 protein from affected and control human fibro-
blasts showed reduced levels of PER2 protein in S662G
mutants compared withWT but no change in the relative
nuclear content, which was confirmed with the trans-
genic mouse lines. Time-course analysis of mRNA tran-
scripts from transgenic mouse tissue showed that
hPER2 and endogenous mouse (m) Per2 peak earlier in
S662G mice compared with WT, consistent with the
ASP phenotype, and as expected, the S662D mice had
later peaks. Both mPer2 and hPER2 RNA levels were
reduced in the S662G line, consistent with a stronger tran-
scriptional repressor activity on CLOCK/BMAL1 by the
mutant S662G PER (Kaasik et al., 2013; Xu et al., 2007).
In another smaller FASP kindred (K5231), a candidate
gene sequencing approach for known circadian genes
was employed to screen members of the family. An
A-to-G change was identified in the DNA sequence of
CKIδ, which results in an amino acid change at position
44 from a threonine to alanine in the protein (CK1δ
T44A) (Xu et al., 2005). This mutation cosegregated with
the phenotype in the family and was novel. Phylogenetic
analysis of this residue showed conservation in humans,
mouse, and Drosophila, suggesting its importance in
kinase function across species. In vitro analysis of the
CK1δ T44A compared with WT showed that it has
decreased kinase activity for the exogenous substrates
phosvitin and α-casein and even further reduced phos-
phorylation of PER 1–3 substrates. Transgenic mice were
created containing the appropriate cis-regulatory ele-
ments with either mutant hCK1δ-T44A or wild-type
hCK1δ-WT genes to evaluate the effect of the mutation
in vivo. In DD, period length was significantly shortened
in the hCK1δ-T44A (23.4 h) versus hCK1δ-WT (23.8 h),
and mCK1δ heterozygous (+/) mice had a period of
23.7 h. Activity of behavior in LD 12:12 did not reveal a
sleep phase advance.When reentraining to LD 12:12 from
an extended period of DD, a deficit in time to reentrain-
ment was observed in the hCK1δ-T44A mutant animals.
Because CK1δ was known to regulate PER2 function in
modulating clock speed and circadian timing, the effect
of crossing hPER2-S662G, hPER2-S662D, and hPER2-
WT to hCK1δ-WT or mCK1δ+/ mice was examined
(Xu et al., 2007; Zhang et al., 2013). Period length of the
crosses derived from the mutant but not the WT hPER2
transgenic mice was affected. Crosses of hPER2-S662G
and hCK1δ-WT shortened period by an additional hour
(20.8 h) compared with hPER2-S662G (22.0 h). When
hPER2-S662G was crossed to the mCK1d+/, period
was lengthened (22.3 h) compared with control hPER2-
S662G animals. These experiments suggest that decreas-
ing CK1δ dosage lengthens period for hPER2-S662G or,
conversely, increasing CK1δ dosage shortens period of
S662G mutants. This experiment further supports the
notion that the PER2 S662G site is a critical residue for
the downstream phosphorylation cascade by CK1δ.
When this site is unable to be phosphorylated, subse-
quent phosphorylation of downstream sites is blocked,
and other sites outside of this region are phosphorylated.
This leads to targeting of PER2 for degradation, thus tip-
ping the equilibrium toward reduced PER2 levels and
causing shortened period. These data confirm that the
posttranslational regulation of PER2 is sufficient to cause
FASP and, importantly, have implications for the regula-
tion of sleep timing in the human population more gen-
erally. Interestingly, the mutation carriers in this family
all have migraine, and notably, an additional allele,
CSNK1D-H46R, has also been identified to be associated
with FASP and familial migraine. The role of CSNK1D in
causing FASP with migraine was further supported by
in vitro and in vivo experiments (Brennan et al., 2013).
Candidate gene screening was again applied to
another small-sized FASP kindred (K50035), identifying
a missense mutation in the human CRY2 gene that con-
verts an alanine to threonine at position 260 in the amino
acid sequence (A260T) that cosegregates with affected
individuals (Hirano et al., 2016). The proband’s FASP
phenotype was confirmed with melatonin sampling,
with an onset that is advanced by >4 h (4:40 p.m.
compared with 8:50 p.m. for unaffected individuals).
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The A260T mutation site is a highly conserved residue in
vertebrates and is in the FAD-binding domain of CRY2.
In vitro analysis of this mutation revealed that the
A260T mutation has reduced repressor activity on
CLOCK-/BMAL1-mediated transcription and that the
mutated protein was more unstable compared with WT
(Hirano et al., 2016). FBXL3 promotes the degradation
of CRY2 through its association with the FAD-binding
pocket (Xing et al., 2013). Because the mutation is located
in the FAD-binding region, it was postulated that it
alters the CRY2-FBXL3 interaction and promotes the
instability of hCRY2-A260T. By knocking down FBXL3
in cultured cells, hCRY2-A260T stability was restored.
Because FAD stabilizes CRY2 by interfering with the
CRY2-FBXL3 interaction (Hirano et al., 2016), the ability
of FAD to protect CRY2 from FBXL3 was interrogated
using a competitive binding assay. When FAD was
added to the assay, free hCRY2-WT protein levels were
released in a dose-dependent manner, while hCRY2-
A260T protein remained bound more tightly to FBXL3.
Structural modeling of this mutation confirmed changes
in the binding pocket that likely renders hCRY2-A260T
more accessible to FBXL3.
Transgenic mice carrying the mutation (hCRY2-
A260T) or wild-type (hCRY2-WT) genes were generated
to test whether the A260T mutation causes FASP. In
behavioral analyses under LD 12:12, hCRY2-A260T mice
exhibited an earlier peak of resting behavior and activity
onset and offset compared with hCRY2-WTmice. Period
length was assessed in DD, and hCRY2-A260T had a
shortened period (23.5 h) compared with hCRY2-WT
(23.7 h). Both the advanced phase and shortened period
behaviors are consistent with previous reports of FASP
(Xu et al., 2007). To summarize these findings, the
hCRY2-A260T causes a conformational change in the
FAD-binding pocket of CRY2, increasing its net interac-
tion with FBXL3, thus promoting its degradation and
leading to reduced repressor activity on the CLOCK/
BMAL1 heterodimer. This causes period shortening
and advanced phase in the mouse and human. Because
FAD is a key component in multiple metabolic pathways,
a second set of experiments examined whether FAD can
alter the stability of CRY2 and, thus, affect circadian
rhythms in mice (Hirano, Braas, Fu, & Ptácek, 2017).
Indeed, these complimentary experiments showed that
FAD stabilizes CRY2 and increases period length in a
dose-dependent manner in vitro. In vivo, components of
the FAD synthetic pathway oscillate in a circadian man-
ner, and knockdown of riboflavin kinase (Rfk, biosyn-
thetic enzyme of FAD) alters clock gene expression
(largely reduces expression) in the liver. Since FAD is
derived from riboflavin (vitamin B2), these data suggest
a novel pathway (informed by the findings in the FASP
work) in the dietary andmetabolic regulation of circadian
proteins in peripheral tissues.
A mutation in PER3 was identified in another small
FASP kindred (K7107) with higher Beck Depression
Inventory and seasonality scores, suggesting an overlap-
ping seasonal affective disorder (SAD) phenotype (Zhang
et al., 2016). Members of this family had a phase advance
of roughly 4 h. The candidate circadian gene sequencing
approach was applied and identified two missense vari-
ants on the same allele: a C-to-G change and an A-to-G
change in PER3,which causes a proline-to-alanine amino
acid change at 415 and histidine-to-arginine change
at 417 in the protein. These rare variants were found to
be conserved in vertebrate species, cosegregated with
affected familymembers, and not identified in 250 control
subjects. In vitro analysis of this variant demonstrated
that hPER3-P415A/H417R has reduced repressor activ-
ity for CLOCK-/BMAL1-mediated transcription and
reduced stability in the nucleus and cytoplasm compared
with hPER3-WT. Previous studies had shown that PER3
affects the stability of PER1 and PER2. Here, hPER3-WT
was found to help stabilize PER1 and PER2, and hPER3-
P415A/H417R lost this stabilizing effect of PER1 and
PER2. Wild-type (hPER3-WT) and mutant (hPER3-
P415A/H417R) mice were generated and subjected to
behavioral testing. Under standard LD 12:12 andDD con-
ditions, there was no observed behavioral difference in
phase or period length. Because of the seasonal light
and mood sensitivity in the FASP human subjects, the
mice were subjected to constant light (LL) and 4 h
light/20 h dark (LD 4:20) to simulate extreme seasonal
conditions. In LL, the period of hPER3-P415A/H417R
mice was significantly longer (25.6 h) than that of hPER3-
WTmice (24.9 h). In the LD 4:20 condition, hPER3-P415A/
H417R mice had a dramatically altered phase in activity
onset and offset patterns compared with WT and dis-
played lower amplitude of activity rhythms in the
wheel-running paradigm used to assay rest/activity
behavior. Tail suspension and forced swim tests (used
as test for depression-like behavior) showed increased
immobile time in hPER3-P415A/H417R mice compared
with hPER3-WT, suggesting depression-like behavior,
which was rescued with the administration of the antide-
pressant imipramine. Measures of depression-like behav-
ior worsened when the mice were subjected to a short
photoperiod, consistent with the phenotype of humans
with seasonal affective disorder (Zhang et al., 2016).
These data provide further insight into a developing
mechanistic link between circadian rhythm maintenance
and mood stabilization (Vadnie & McClung, 2017).
Common features of the reported FASP mutations
include mutations in the key negative regulatory limb
of themolecular circadian clock, altered repressor activity
of the canonical heterodimer CLOCK/BMAL1, and pro-
tein instability of the mutated proteins, leading to alter-
ations in period and changes in behavioral phase.
However, it is possible that screens for FASP could yield
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information on mutations that do not affect period, but
specifically affect entrainment to light or coupling to
other proteins that affect processes regulating sleep tim-
ing downstream of the clock itself. An in-depth investiga-
tion of FASP families has yielded substantial insight into
the regulation of the circadian clock, particularly in its
posttranslational modifications. This knowledge offers
an opportunity to develop therapies in the future to
adjust clock speed or phase in humans or better track
and understand an individual’s phase to appropriately
time the administration of certain sensitive medications
like chemotherapy or vaccinations. An interesting oppor-
tunity lies with ASP that commonly affects the elderly;
due to its telomeric location, PER2 expression could be
affected by epigenetic changes associated with the aging
process, causing the increased prevalence of ASP. It is
possible that, by modulating the phosphorylation of
PER2 and increasing its stability, one could mitigate
against this condition in elderly populations.
Sleep homeostasis traits include extreme variations in an
individual’s requirement or need for sleep. A 54-nucleotide
variable number tandem repeat in exon 18 of the PER3
gene has been associated with changes in slow-wave sleep
during normal conditions and in recovery sleep after sleep
deprivation. Individuals who are homozygous for the
5-repeat allele (PER3 5/5) have increased slow-wave activ-
ity in NREM sleep and increased alpha activity in REM
sleep during baseline sleep that persist after sleep depriva-
tion compared with individuals who are homozygous for
four-tandem repeats (PER3 4/4) (Viola et al., 2012). Perfor-
mance on neurocognitive tests during and after sleep dep-
rivation is worse in PER3 5/5 compared with PER3 4/4
individuals (Viola et al., 2007). This polymorphism is also
associated with self-reported adaptation to shift work in
nurses and sleepiness during and after work shifts
(Gamble et al., 2011).
Familial natural short sleep (FNSS): While evaluating
human subjects with FASP, some individuals were noted
not only to wake extremely early but also to fall asleep
much later than typical FASP individuals. Further charac-
terization of these families led to the recognition of an
autosomal dominant familial form of natural short sleep
(FNSS). The characteristic trait is a lifelong requirement of
daily sleep time of approximately 6 h or less (He et al.,
2009; Jones et al., 2012). FNSS individuals do not report
a need for additional sleep or complain of sleepiness
and perform well on cognitive testing under normal
conditions. Although mouse models of some circadian
clock genes were found to exhibit altered sleep home-
ostasis (Mang & Franken, 2013), FNSS was postulated
to be the first human mutation recognized (not by associ-
ation) to cause a specific sleep homeostasis (Process S)
phenotype, as total sleep time is reduced in these indi-
viduals with otherwise stable circadian rhythmicity
(Process C).
Kindred 7430 is a small family with two affected indi-
viduals (He et al., 2009). Sleep onset was roughly 10 p.m.
with offset around 4 a.m. without an obvious phase phe-
notype. Sequencing of DNA identified a mutation in the
DEC2 (a transcriptional repressor known to inhibit
CLOCK-/BMAL1-mediated transcription) gene with a
proline-to-arginine alteration at amino acid 384 (hDEC2
P384R) in the protein that segregatedwith the phenotype.
Phylogenetic analysis revealed conservation in mammals
in a highly conserved proline-rich region near theHDAC-
binding domain of unclear function. In vitro assays deter-
mined that the mutation reduced DEC2 transcriptional
repression of CLOCK/BMAL1 (He et al., 2009). Trans-
genic mice carrying the DEC2-P384R mutation (hDEC2-
P384R) and wild type (hDEC2-WT) were subjected to
circadian behavioral analysis and demonstrated no dif-
ference in free-running period in the DD condition. How-
ever, the duration of activity was significantly increased
in hDEC2-P384 animals by 1.2 h. The hDEC2-P384Rmice
and WT littermate controls were then subjected to EEG
analysis of sleep/wake behavior. Mutant mice had a sig-
nificantly longer period of wakefulness and correspond-
ing reduction in NREM and REM sleep. Analysis of EEG
delta power across light and dark periods showed a non-
significant increase at all times in the hDEC2-P384R line
compared with controls. After 6 h of sleep deprivation
in the first 6 h of the light period, mutant mice showed
less NREM delta power in the rest phase immediately
following the sleep deprivation protocol and less subse-
quent NREM and REM rebound sleep compared with
WT controls, suggesting a decreased effect of sleep dep-
rivation on the mutant animals. These data collectively
indicate that the hDEC2-P384R mutation, indeed, causes
a short sleep phenotype and may play a role in an accel-
erated recovery after sleep deprivation.
A separate experiment attempted to validate the finding
thatDEC2 variants are involved in sleep homeostasis. Two
large cohorts of twins, 59 monozygotic twins and 41 dizy-
gotic twins, were subjected to acute sleep deprivation for
38 h (Pellegrino et al., 2014). EEGwas applied to objectively
quantify sleep-wake behavior, and subjects performed a
10 min psychomotor vigilance reaction time test during
the sleep deprivation period. A novel variant in DEC2
1086 C-to-T nucleotide change corresponding to a change
from tyrosine to histidine at position 362 (Y362H) in the
amino acid sequence was found in a dizygotic twin pair
(one noncarrier and one carrier) that was associated with
fewer performance lapses during sleep deprivation and less
total recovery sleep time after sleep deprivation (Pellegrino
et al., 2014). Examination of the repressive activity of DEC2-
Y362H in vitro demonstrated reduced activity, consistent
with the findings for DEC2-P384R. Another recent study
examined DEC2 repressor activity and its relationship with
the orexin pathway in sleep homeostasis. The expression of
orexin was upregulated in hDEC2-P384R mice in the
177III HERITABLE SLEEP TRAITS
PART B. REGULATION OF WAKING AND SLEEPING
hypothalamus at the transition from wake to sleep. In vitro
assays demonstrated that DEC2 inhibits E-box-mediated
transcription of prepro-orexin and that the P384R muta-
tion decreases DEC2 repressor activity that is mediated
through its binding and interaction with the MyoD1/
E12 heterodimer (which drives the expression of prepro-
orexin). The formation of the DEC2/MyoD1/E12 complex
wasweakened by the P384Rmutation leading to increased
prepro-orexin at the transition from wake to sleep, sug-
gesting DEC2 regulates sleep duration, in part, by modu-
lating the orexin signaling pathway (Hirano et al., 2018).
FNSS is a newly recognized entity in sleep genetics.
While the exact roles of sleep are largely unknown
(i.e., likely important for toxin clearance, synaptic homeo-
stasis, and metabolic rebalancing), FNSS individuals
appear to be efficient sleepers who are able to execute
the necessary functions of sleep in a shorter amount of
time and exhibit a higher resilience to sleep deprivation.
IV CONCLUSIONS
Due to the complexity of sleep behavior and the sig-
nificant influence of the environment on sleep traits, del-
ineating the pathways of sleep regulation has been a
challenging enterprise. Using a methodical approach to
phenotyping involving the objective characterization of
sleep and circadian behavior in families with heritable
sleep traits has led to the identification of genetic variants
and subsequent characterization of molecular pathways
in animal models by taking advantage of the conserved
nature of this indispensable process. Insights obtained
from FASP have pointed to the importance of posttrans-
lational modification of circadian proteins to change cir-
cadian period or phase and fine-tune circadian timing.
Further, FNSS constitutes an exciting field of research,
where the identification of the first molecular pathways
that regulate sleep duration now opens new opportuni-
ties to better understand sleep homeostasis. Understanding
the fundamentals behind the timing and efficiency of
sleep provides a framework that will allow for improved
characterizationof individual circadianphaseor sleepneed,
more informed timing of medication delivery to improve
efficacy, and, more broadly, the opportunity for the devel-
opment of new therapies to assist with the consequences of
sleep and circadian disruption in humans.
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